EGFR and non-small cell lung carcinoma: Dacomitinib (PF-00299804), a pan-EGFR-family irreversible inhibitor is currently in several trials for NSCLC, such as phase 2trial NCT01858389 for advanced NSCLC, phase 3 NCT01360554 comparing dacomitinib and erlotinib, phase 3 NCT01774721/ARCHER 1050 comparing dacomitinib versus gefitinib, phase 3 NCT01000025 for patients with advanced NSCLC who have not responded to previous therapies, and several more.